CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction Ejection Fraction Pros and Cons: JACC State-of-the-Art Review In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate

Review ArticleVolume 76, Issue 6, August 2020

JOURNAL:J Am Coll Cardiol. Article Link

Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel

JE Wilcox, JC Fang, KB Margulies et al. Keywords: heart failure with recovered ejection fraction; myocardial recovery

ABSTRACT

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction. A growing body of evidence suggests that even among patients who experience a complete normalization of LV ejection fraction, a significant proportion will develop recurrent LV dysfunction accompanied by recurrent heart failure events. This has led to intense interest in understanding how to manage patients with heart failure with recovered ejection fraction (HFrecEF). Because of the lack of a standard definition for HFrecEF, and the paucity of clinical data with respect to the natural history of HFrecEF patients, there are no current guidelines on how these patients should be followed up and managed. Accordingly, thisJACCScientific Expert Panel reviews the biology of reverse LV remodeling and the clinical course of patients with HFrecEF, as well as provides guidelines for defining, diagnosing, and managing patients with HFrecEF.